Article: Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
AuthorsPhua, KB1
Lim, FS4
Lau, YL2
Nelson, EAS8
Huang, LM5
Quak, SH6
Lee, BW7
Teoh, YL3 4
Tang, H3
Boudville, I3
Oostvogels, LC3
Suryakiran, PV3
Smolenov, IV3
Han, HH3
Bock, HL3
Issue Date2009
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2009, v. 27 n. 43, p. 5936-5941 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2009.07.098
AbstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2009.07.098
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorPhua, KB
dc.contributor.authorLim, FS
dc.contributor.authorLau, YL
dc.contributor.authorNelson, EAS
dc.contributor.authorHuang, LM
dc.contributor.authorQuak, SH
dc.contributor.authorLee, BW
dc.contributor.authorTeoh, YL
dc.contributor.authorTang, H
dc.contributor.authorBoudville, I
dc.contributor.authorOostvogels, LC
dc.contributor.authorSuryakiran, PV
dc.contributor.authorSmolenov, IV
dc.contributor.authorHan, HH
dc.contributor.authorBock, HL
dc.date.accessioned2012-10-30T06:08:26Z
dc.date.available2012-10-30T06:08:26Z
dc.date.issued2009
dc.description.abstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2009, v. 27 n. 43, p. 5936-5941 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2009.07.098
dc.identifier.citeulike5432708
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2009.07.098
dc.identifier.epage5941
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue43
dc.identifier.pmid19679216
dc.identifier.scopuseid_2-s2.0-70349431081
dc.identifier.spage5936
dc.identifier.urihttp://hdl.handle.net/10722/170422
dc.identifier.volume27
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.subject.meshChild, Preschool
dc.subject.meshDouble-Blind Method
dc.subject.meshGastroenteritis - Prevention & Control - Virology
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshRotavirus Infections - Prevention & Control
dc.subject.meshRotavirus Vaccines - Administration & Dosage
dc.subject.meshVaccines, Attenuated - Administration & Dosage
dc.titleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
dc.typeArticle
Author Affiliations
  1. KK Women's And Children's Hospital
  2. The University of Hong Kong
  3. GlaxoSmithKline
  4. National Healthcare Group Polyclinics, Singapore
  5. National Taiwan University Hospital
  6. National University of Singapore
  7. Mount Elizabeth Medical Centre
  8. Chinese University of Hong Kong